Clinical diagnostics and healthcare company Alere today announced the European launch of the Alere i platform and Influenza A & B test, a molecular assay designed to detect and differentiate those viruses in less than 15 minutes.

The test and Alere i platform, which uses isothermal nucleic acid amplification technology to facilitate point-of-care testing, is now commercially available in Austria, France, Spain, Switzerland, Germany, Italy, and the UK. The test is not yet available in the US but is currently under regulatory review by the US Food and Drug Administration.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

A trial upgrade to 360Dx Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try 360Dx Premium now.

Already a 360Dx Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.